Application progression of new nucleos(t)ide analogues in hepatitis B related liver transplantation

doi:10.3877/cma.j.issn.1674-3903.2021.05.010

Abstract

Abstract:

Hepatitis B virus (HBV) reactivation is one of the common problems faced by HBV-related recipients after liver transplantation. Recently, the application of nucleos(t)ide analogues (NAs) has greatly reduced the recurrence rate of HBV after liver transplantation, and long-term medication has also brought many disadvantages, such as drug resistance, kidney damage. Tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide fumarate (TAF) are both high genetic barrier NAs, and clinical applications show that they have good efficacy and tolerability, especially NAs monoprophylaxis have a good application prospect against HBV reactivation after liver transplantation. This article reviews the latest application progress of TDF and TAF after liver transplantation.

Key words: Nucleos(t)ide analogues, Hepatitis B, Liver transplantation, Tenofovir disoproxil fumarate, Tenofovir alafenamide fumarate

Huimin Zhai, Man Xie, Xinjuan Kong, Wei Rao. Application progression of new nucleos(t)ide analogues in hepatitis B related liver transplantation[J]. Chinese Journal of Transplantation(Electronic Edition), 2021, 15(05): 302-306.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhyzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3903.2021.05.010

https://zhyzzz.cma-cmc.com.cn/EN/Y2021/V15/I05/302

References 46

1	WHO. Global hepatitis report, 2017[EB/OL]. (2019-11-06)[2021-03-31]. URL
2	王贵强，王福生，庄辉，等. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志，2019, 35(12)：2648-2669.
3	Pfitzmann R, Nussler NC, Hippler-Benscheidt M, et al. Long-term results after liver transplantation[J]. Transpl Int, 2008, 21(3)：234-246.
4	Todo S, Demetris AJ, Van Thiel D, et al. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease[J]. Hepatology, 1991, 13(4)：619-626.
5	O′Grady JG, Smith HM, Davies SE, et al. Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications[J]. J Hepatol, 1992, 14(1)：104-111.
6	Lake JR, Wright TL. Liver transplantation for patients with hepatitis B: What have we learned from our results？[J]. Hepatology, 1991, 13(4)：796-799.
7	Terrault NA, Bzowej NH, Chang KM, et al. AASLD guidelines for treatment of chronic hepatitis B[J]. Hepatology, 2016, 63(1)：261-283.
8	Lok AS, McMahon BJ, Brown RS, et al. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis[J]. Hepatology, 2016, 63(1)：284-306.
9	Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy[J]. J Hepatol, 2012, 57(2)：442-450.
10	Singal AK, Fontana RJ. Meta-analysis：oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis[J]. Aliment Pharmacol Ther, 2012, 35(6)：674-689.
11	Boglione L, D′Avolio A, Cariti G, et al. Telbivudine in the treatment of hepatitis B-associated cryoglobulinemia[J]. J Clin Virol, 2013, 56(2)：167-169.
12	Mazzaro C, Dal Maso L, Urraro T, et al. Hepatitis B virus related cryoglobulinemic vasculitis：A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie - GISC[J]. Dig Liver Dis, 2016, 48(7)：780-784.
13	Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4)：1560-1599.
14	Jimenez-Perez M, Gonzalez-Grande R, Mostazo Torres J, et al. Management of hepatitis B virus infection after liver transplantation[J]. World J Gastroenterol, 2015, 21(42)：12083-12090.
15	Westin J, Aleman S, Castedal M, et al. Management of hepatitis B virus infection, updated Swedish guidelines[J]. Infect Dis (Lond), 2020, 52(1)：1-22.
16	De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections[J]. Clin Microbiol Rev, 2003, 16(4)：569-596.
17	Heathcote EJ, Marcellin P, Buti M, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B[J]. Gastroenterology, 2011，140(1)：132-143.
18	Giesler KE, Liotta DC. Next-generation reduction sensitive lipid conjugates of tenofovir: Antiviral activity and mechanism of release[J]. J Med Chem, 2016, 59(22)：10244-10252.
19	任天棋，杨倩倩，马鹤铭，等. TAF治疗慢性乙型肝炎的研究进展[J]. 肝脏，2019, 24(11)：1319-1322.
20	Buti M, Gane E, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection：a randomised，double-blind, phase 3，non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3)：196-206.
21	Murakami E, Wang T, Park Y, et al. Implications of efficient hepatic delivery by tenofovir alafenamide (GS-7340) for hepatitis B virus therapy[J]. Antimicrob Agents Chemother, 2015, 59(6)：3563-3569.
22	Cholongitas E, Tziomalos K, Pipili C. Management of patients with hepatitis B in special populations[J]. World J Gastroenterol, 2015, 21(6)：1738-1748.
23	Tanaka T, Renner EL, Selzner N, et al. One year of hepatitis B immunoglobulin plus tenofovir therapy is safe and effective in preventing recurrent hepatitis B post-liver transplantation[J]. Can J Gastroenterol Hepatol, 2014, 28(1)：41-44.
24	Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: A systematic review[J]. Am J Transplant, 2013, 13(2)：353-362.
25	Cholongitas E, Goulis I, Antoniadis N, et al. New nucleos(t)ide analogue monoprophylaxis after cessation of hepatitis B immunoglobulin is effective against hepatitis B recurrence[J]. Transpl Int, 2014, 27(10)：1022-1028.
26	Manini MA, Whitehouse G, Bruce M, et al. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal[J]. Dig Liver Dis, 2018, 50(9)：944-953.
27	Rashidi-Alavijeh J, Straub K, Achterfeld A, et al. Safety and efficacy of tenofovir alafenamide in liver transplant recipients：A single center experience[J]. Transpl Infect Dis, 2020：e13522.
28	Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection：a randomised，double-blind, phase 3, non-inferiority trial[J]. Lancet Gastroenterol Hepatol, 2016, 1(3)：185-195.
29	Saab S, Song D, Challita YP, et al. Long-term outcomes with oral therapy in liver transplant recipients with hepatitis B[J]. Clin transplant, 2019：e13740.
30	Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B[J]. Aliment Pharmacol Ther, 2012, 35(11)：1317-1325.
31	Wong GL, Tse YK, Wong VW, et al. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53，500 subjects[J]. Hepatology, 2015, 62(3)：684-693.
32	Lee D, Yun BC, Seo KI, et al. Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate[J]. Medicine, 2019, 98(50)：e18351.
33	Vasudevan A, Ardalan ZS, Ahmed N, et al. Long-term safety and efficacy of tenofovir disoproxil fumarate substitution for hepatitis B immunoglobulin following liver transplantation[J]. JGH Open, 2018, 2(6)：288-294.
34	Wong GL, Seto WK, Wong VW, et al. Review article：long-term safety of oral anti-viral treatment for chronic hepatitis B[J]. Aliment Pharmacol Ther, 2018, 47(6)：730-737.
35	Sripongpun P, Mannalithara A, Kwo PY, et al. Potential benefits of switching liver transplant recipients to tenofovir alafenamide prophylaxis[J]. Clin Gastroenterol Hepatol, 2020, 18(3): 747-749.
36	European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2)：370-398.
37	European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection[J]. J Hepatol, 2012, 57(1)：167-185.
38	Rockstroh JK, Bhagani S, Benhamou Y, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults[J]. HIV Med, 2008, 9(2)：82-88.
39	Yang JX, Liu BM, Li XG, et al. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients[J]. Antivir Ther, 2010, 15(8)：1171-1178.
40	Tan J, Degertekin B, Wong SN, et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations[J]. J Hepatol, 2008, 48(3)：391-398.
41	Jiang D, Wang J, Zhao X, et al. Entecavir resistance mutations rtL180M/T184L/M204V combined with rtA200V lead to tenofovir resistance[J]. Liver Int, 2020, 40(1)：83-91.
42	Park ES, Lee AR, Kim DH, et al. Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients[J]. J Hepatol, 2019, 70(6)：1093-1102.
43	Cathcart AL, Chan HL, Bhardwaj N, et al. No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis B infection[J]. Antimicrob Agents Chemother, 2018, 62(10)：e01064-18.
44	Yeh CT, Chien RN, Chu CM, et al. Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy[J]. Hepatology, 2000, 31(6)：1318-1326.
45	Yatsuji H, Noguchi C, Hiraga N, et al. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif[J]. Antimicrob Agents Chemother, 2006, 50(11)：3867-5874.
46	Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure[J]. J Antimicrob Chemother, 2008, 48(5)：747-755.

[1]	Jiansong Gao, Xiaoxiao Chen, Ting Feng, Jianfeng Bao, Shufang Wei, Lin Pan. Ultrasonic elastography based multiparameteric decision tree model for assessment of grade of liver fibrosis in patients with chronic hepatitis B [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 923-929.
[2]	Xiaoman Zhang, Xiaoqiu Ma, Zhengju Xu, Chunyu Zhang, Caiting He. Effect of drug-resistant mutations in reverse transcriptase region of hepatitis B virus on the level of serum hepatitis B surface antigen [J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2023, 17(05): 324-332.
[3]	Kunhe Li, Mengjia Kou, Liting Kuang. Risk factors and prediction model of reintubation after liver transplantation [J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(05): 366-371.
[4]	Fangyuan Wu, Xia Sun, Changfeng Lin, Zhensheng Zhang. Risk factors of HBV-associated cirrhosis complicated with acute upper gastrointestinal bleeding [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 45-47.
[5]	Branch of Organ Transplant of Chinese Medical Association, Branch of Organ Transplant Physicians of Chinese Medical Doctor Association, Shanghai Pharmaceutical Profession Association. Expert Consensus on the Use of Mycophenolic Acid in Chinese Liver and Kidney Transplant Recipients (2023 edition) [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 257-272.
[6]	Wenqing Lu, Xinyi Chen, Xuefei Ren. Investigation on the quality of life after liver transplantation in children with genetic metabolic diseases [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 287-292.
[7]	Tieyan Fan, Jun Li, Hong Chen. Diagnosis and treatment experience of new onset viral hepatitis E after liver transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 293-296.
[8]	Shuo Chen, Feng Chen, Fei Cheng, Jie Xiang. Pancreas infarction after liver transplantation for glycogen storage disease type Ⅰ complicated with pancreatitis: a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(05): 300-302.
[9]	Qing Yan, Ying Liu, Feiwen Deng, Huanwei Chen. Effect of microvascular invasion on survival and prognosis of liver transplantation recipients with liver cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 624-629.
[10]	Mei Liao, Hongjun Zhang, Jieyang Jin, Yan Lyu, Jie Ren. Diagnostic value of bedside contrast-enhanced ultrasound for early hepatic artery thrombosis after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 630-634.
[11]	Binglin Li, Shaocheng Lyu, Fei Pan, Tao Jiang, Hua Fan, Jiantao Kou, Qiang He, Ren Lang. Correlation analysis between pathogenic bacteria of donor liver perfusion fluid and early infection after liver transplantation [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 656-660.
[12]	Lei Lyu, Xiao Feng, Kaiming He, Kaining Zeng, Qing Yang, Haijin Lyu, Huimin Yi, Shuhong Yi, Yang Yang, Binsheng Fu. Value of revised King's score in evaluation of live transplantation timing for children with acute liver failure due to Wilson's disease and literature review [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(06): 661-668.
[13]	Menglong Wang. Significance of biological characteristics in liver transplantation for HCC [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 490-494.
[14]	Shudian Chen, Yun Liang, Yuan Liao, Yang Wang. Prognostic value of complement C3 in patients with HBV-related acute-on-chronic liver failure [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(05): 562-566.
[15]	Fanbiao Kong, Jianrong Yang. Progress in understanding of relationship between underlying liver diseases and liver metastasis of colorectal cancer [J]. Chinese Journal of Clinicians(Electronic Edition), 2023, 17(07): 818-822.

Please choose a citation manager

Content to export